ATE256698T1 - Biologisch aktive peptide und ihre zubereitungen und verwendungen - Google Patents

Biologisch aktive peptide und ihre zubereitungen und verwendungen

Info

Publication number
ATE256698T1
ATE256698T1 AT96910116T AT96910116T ATE256698T1 AT E256698 T1 ATE256698 T1 AT E256698T1 AT 96910116 T AT96910116 T AT 96910116T AT 96910116 T AT96910116 T AT 96910116T AT E256698 T1 ATE256698 T1 AT E256698T1
Authority
AT
Austria
Prior art keywords
preparations
biologically active
active peptides
derivatives
geodiamolide
Prior art date
Application number
AT96910116T
Other languages
English (en)
Inventor
Raymond Andersen
Chemistry
John Coleman
Silva Dilip De
Fangming Kong
Edward Piers
Debra Wallace
Michel Roberge
Biochemistry
Theresa Allen
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE256698T1 publication Critical patent/ATE256698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96910116T 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen ATE256698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9508195.6A GB9508195D0 (en) 1995-04-20 1995-04-20 Novel biologically active compounds and compositions,their use and derivation
PCT/GB1996/000942 WO1996033211A1 (en) 1995-04-20 1996-04-22 Biologically active peptides and compositions, their use

Publications (1)

Publication Number Publication Date
ATE256698T1 true ATE256698T1 (de) 2004-01-15

Family

ID=10773352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910116T ATE256698T1 (de) 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen

Country Status (12)

Country Link
US (4) US6153590A (de)
EP (1) EP0839154B1 (de)
JP (2) JP4008493B2 (de)
AT (1) ATE256698T1 (de)
AU (1) AU5341696A (de)
CA (1) CA2220021C (de)
DE (1) DE69631141T2 (de)
DK (1) DK0839154T3 (de)
ES (1) ES2213173T3 (de)
GB (1) GB9508195D0 (de)
PT (1) PT839154E (de)
WO (1) WO1996033211A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003228354B8 (en) * 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
KR20050054951A (ko) 2002-09-20 2005-06-10 와이어쓰 홀딩스 코포레이션 튜불린 억제제의 합성에 유용한 중간체의 합성방법
US20040121965A1 (en) * 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
US7241866B2 (en) * 2002-10-30 2007-07-10 Merck & Co., Inc. Using amines or amino acids as mobile phase modifiers in chromatography
AU2003295808A1 (en) * 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7390910B2 (en) * 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
US20080242670A2 (en) * 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
WO2006046080A2 (en) * 2004-10-26 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
JP2008540449A (ja) * 2005-05-05 2008-11-20 エーザイ株式会社 （２ｅ，４ｓ）−４−［（ｎ−｛［（２ｒ）−１−イソプロピルピペリジン−２−イル］−カルボニル｝−３−メチル−ｌ−バリル）（メチル）アミノ］−２，５−ジメチルヘキサ−２−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2118127A4 (de) * 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP2240481A1 (de) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinon)-substituierte pyridoindole als mch-antagonisten
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN103570603A (zh) * 2012-07-19 2014-02-12 杭州中肽生化有限公司 哈米特林的一种合成新方法
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
MX2017003476A (es) 2014-09-17 2017-08-02 Zymeworks Inc Compuestos citotoxicos y anti-mitoticos, y metodos para usar los mismos.
AU2016338410B2 (en) 2015-10-14 2021-07-15 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
PT3666787T (pt) * 2017-08-10 2024-03-21 Sumitomo Pharma Co Ltd Conjugados anticorpo-fármaco que incluem um derivado da hemiasterlina
EP4321523A3 (de) 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlinderivate und antikörper-wirkstoff-konjugate damit
WO2020166600A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 システイン残基を有するヘミアスタリン誘導体
JP7437328B2 (ja) * 2019-02-13 2024-02-22 住友ファーマ株式会社 多能性幹細胞の除去剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2904512A1 (de) * 1979-02-07 1980-08-28 Troponwerke Gmbh & Co Kg Dehydropeptide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4820691A (en) 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
US5081225A (en) * 1989-02-09 1992-01-14 E. R. Squibb & Sons, Inc. Gram-positive and gram-negative antibacterial compounds from the microorganism, janthinobacterium lividum
US5340802A (en) * 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2042027A1 (en) * 1989-09-15 1991-03-16 Arthur E. Bogden Treatment of colon cancer
FR2681075B1 (fr) * 1991-09-05 1994-09-16 Commissariat Energie Atomique Preparation enzymatique purifiee issue de chromobacterium violaceum, son procede d'obtention et son application a la production d'alpha,beta-dehydrotryptophanyl-peptides.
WO1993017701A1 (en) * 1992-03-12 1993-09-16 The Administrators Of The Tulane Educational Fund Endothelin receptor-binding peptides
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5661175A (en) * 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof

Also Published As

Publication number Publication date
US20090088573A1 (en) 2009-04-02
ES2213173T3 (es) 2004-08-16
US7772397B2 (en) 2010-08-10
DE69631141D1 (de) 2004-01-29
US6153590A (en) 2000-11-28
JPH11505211A (ja) 1999-05-18
CA2220021A1 (en) 1996-10-24
DK0839154T3 (da) 2004-04-19
US20050171137A1 (en) 2005-08-04
JP4006466B2 (ja) 2007-11-14
EP0839154A1 (de) 1998-05-06
JP2007031441A (ja) 2007-02-08
WO1996033211A1 (en) 1996-10-24
US6870028B1 (en) 2005-03-22
US7410951B2 (en) 2008-08-12
AU5341696A (en) 1996-11-07
EP0839154B1 (de) 2003-12-17
PT839154E (pt) 2004-05-31
DE69631141T2 (de) 2004-09-30
CA2220021C (en) 2012-06-26
JP4008493B2 (ja) 2007-11-14
GB9508195D0 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
ATE256698T1 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
NL350077I2 (nl) Cyprosulfamide
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
PT765152E (pt) Estimulacao do crescimento capilar por complexos de peptido-cobre
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
AU2291097A (en) Novel phenanthridines substituted in the 6 position
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
TR199800623T2 (xx) Yeni amino asit t�revleri, m�stahzarlar� ve kullan�mlar�.
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
ATE380821T1 (de) Zytotoxische depsipeptide
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0839154

Country of ref document: EP

REN Ceased due to non-payment of the annual fee